CA3214020A1 - Novel darpin based cd70 engagers - Google Patents

Novel darpin based cd70 engagers Download PDF

Info

Publication number
CA3214020A1
CA3214020A1 CA3214020A CA3214020A CA3214020A1 CA 3214020 A1 CA3214020 A1 CA 3214020A1 CA 3214020 A CA3214020 A CA 3214020A CA 3214020 A CA3214020 A CA 3214020A CA 3214020 A1 CA3214020 A1 CA 3214020A1
Authority
CA
Canada
Prior art keywords
ankyrin repeat
protein
binding
binding protein
recombinant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3214020A
Other languages
English (en)
French (fr)
Inventor
Christian REICHEN
Nina RESCHKE
Bernd Schlereth
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Molecular Partners AG
Original Assignee
Molecular Partners AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Molecular Partners AG filed Critical Molecular Partners AG
Publication of CA3214020A1 publication Critical patent/CA3214020A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C07K2318/20—Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Lock And Its Accessories (AREA)
  • Ignition Installations For Internal Combustion Engines (AREA)
  • Valve Device For Special Equipments (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA3214020A 2021-04-09 2022-04-07 Novel darpin based cd70 engagers Pending CA3214020A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202163173186P 2021-04-09 2021-04-09
US202163172973P 2021-04-09 2021-04-09
US63/173,186 2021-04-09
US63/172,973 2021-04-09
US202163265181P 2021-12-09 2021-12-09
US63/265,181 2021-12-09
PCT/IB2022/053275 WO2022215032A1 (en) 2021-04-09 2022-04-07 Novel darpin based cd70 engagers

Publications (1)

Publication Number Publication Date
CA3214020A1 true CA3214020A1 (en) 2022-10-13

Family

ID=81386901

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3214020A Pending CA3214020A1 (en) 2021-04-09 2022-04-07 Novel darpin based cd70 engagers

Country Status (9)

Country Link
US (1) US20250074994A1 (cg-RX-API-DMAC7.html)
EP (1) EP4319883A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024513559A (cg-RX-API-DMAC7.html)
KR (1) KR20230169182A (cg-RX-API-DMAC7.html)
AU (1) AU2022252985A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023020685A2 (cg-RX-API-DMAC7.html)
CA (1) CA3214020A1 (cg-RX-API-DMAC7.html)
MX (1) MX2023011978A (cg-RX-API-DMAC7.html)
WO (1) WO2022215032A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL298168A (en) 2020-05-14 2023-01-01 Molecular Partners Ag Multispecific proteins
WO2022190016A1 (en) 2021-03-09 2022-09-15 Molecular Partners Ag Novel darpin based multi-specific t-cell engagers
WO2024251628A1 (en) * 2023-06-06 2024-12-12 Molecular Partners Ag Recombinant cd16a binding proteins and their use
JP2026524079A (ja) 2023-06-06 2026-07-17 モレキュラー パートナーズ アクチェンゲゼルシャフト 組換えcd2結合タンパク質及びその使用
WO2025181039A1 (en) 2024-03-01 2025-09-04 Molecular Partners Ag Therapeutic combinations comprising a multi-specific t cell engager

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100150950A1 (en) * 2006-12-14 2010-06-17 Medarex, Inc. Human antibodies that bind cd70 and uses thereof
EP3974453A3 (en) * 2010-11-16 2022-08-03 Amgen Inc. Agents and methods for treating diseases that correlate with bcma expression
EP3514169B1 (en) * 2010-11-26 2024-03-06 Molecular Partners AG Designed repeat proteins binding to serum albumin
JP2016531920A (ja) * 2013-09-05 2016-10-13 アデュロ・バイオテック・ホールディングス・ヨーロッパ・ベスローテン・フエンノートシャップAduro Biotech Holdings, Europe B.V. Cd70結合ペプチドおよびそれに関連する方法、プロセスおよび用途
US9458211B1 (en) * 2015-04-02 2016-10-04 Molecular Partners Ag Recombinant proteins that simultaneously bind HGF, VEGF-A and serum albumin, comprising ankyrin repeat domains
US11291721B2 (en) * 2016-03-21 2022-04-05 Marengo Therapeutics, Inc. Multispecific and multifunctional molecules and uses thereof
MX2020008183A (es) * 2018-02-01 2020-09-22 Pfizer Anticuerpos especificos para cd70 y sus usos.
TW202010757A (zh) * 2018-04-11 2020-03-16 美商英伊布里克斯公司 具有經受限cd3結合的多重特異性多肽構築體以及相關方法及用途
JP2022535564A (ja) * 2019-06-04 2022-08-09 モレキュラー パートナーズ アクチェンゲゼルシャフト 多選択性タンパク質
EP3980452A1 (en) * 2019-06-04 2022-04-13 Molecular Partners AG Recombinant 4-1bb binding proteins and their use
WO2022190016A1 (en) * 2021-03-09 2022-09-15 Molecular Partners Ag Novel darpin based multi-specific t-cell engagers

Also Published As

Publication number Publication date
KR20230169182A (ko) 2023-12-15
US20250074994A1 (en) 2025-03-06
WO2022215032A1 (en) 2022-10-13
JP2024513559A (ja) 2024-03-26
EP4319883A1 (en) 2024-02-14
BR112023020685A2 (pt) 2023-12-12
MX2023011978A (es) 2023-11-17
AU2022252985A1 (en) 2023-11-16

Similar Documents

Publication Publication Date Title
US20240150475A1 (en) Novel darpin based cd123 engagers
US20250074994A1 (en) Novel darpin based cd70 engagers
US20240317852A1 (en) Novel darpin based cd33 engagers
TWI825086B (zh) Her3抗原結合分子
KR20220086554A (ko) Her3 항원-결합 분자를 사용한 암의 치료 및 예방
US20220242973A1 (en) Recombinant fap binding proteins and their use
US11834504B2 (en) DARPin based multi-specific t-cell engagers
US20240052033A1 (en) Recombinant cd3 binding proteins and their use
JP2023553697A (ja) グリピカン-3およびt細胞受容体を標的とする免疫グロブリン単一可変ドメインを含むポリペプチド
WO2024251628A1 (en) Recombinant cd16a binding proteins and their use
EP4724473A1 (en) Recombinant cd47 binding proteins and their use
CN121263440A (zh) 重组cd2结合蛋白及其用途
CN117242100A (zh) 基于DARPin的新型CD70接合物
CN117255803A (zh) 基于DARPin的新型CD33接合物
CN117177996A (zh) 基于DARPin的新型CD123接合物
WO2025146490A1 (en) Recombinant cd117 binding proteins and their use
CN116802213A (zh) 重组cd3结合蛋白及其用途

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250325

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250325

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250325

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260519

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260526